Microflora Disturbance during Progression of Glucose Intolerance and Effect of Sitagliptin: An Animal Study

Journal of Diabetes Research

Volumn 2016, Issue , 2016, Pages

  Yan, Xinfeng ^a   Feng, Bo ^a   Li, Peicheng ^a   Tang, Zhaosheng ^a   Wang, Lin ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; PROBIOTIC AGENT; RNA 16S; SHORT CHAIN FATTY ACID; SITAGLIPTIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ACTINOBACTERIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACILLUS; BACTERIUM; BACTEROIDES; BACTEROIDETES; BIFIDOBACTERIUM; BLAUTIA; BODY WEIGHT; CLOSTRIDIUM; CONTROLLED STUDY; DIABETIC OBESITY; DNA EXTRACTION; DYSBIOSIS; FECES ANALYSIS; FIRMICUTES; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; INTESTINE FLORA; LACTOBACILLUS; LEAN BODY WEIGHT; MALE; MOLLICUTES; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PARABACTEROIDES; PHYLUM; PREVOTELLACEAE; PROTEOBACTERIA; PYROSEQUENCING; RAT; RNA GENE; ROSEBURIA; RUMINOCOCCUS; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; DIABETES COMPLICATIONS; DISEASE COURSE; DRUG EFFECTS; METABOLISM; MICROBIOLOGY; PHYSIOLOGY;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES COMPLICATIONS; DISEASE PROGRESSION; GASTROINTESTINAL MICROBIOME; GLUCOSE INTOLERANCE; HYPOGLYCEMIC AGENTS; RATS; SITAGLIPTIN PHOSPHATE;

EID: 84984673741     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2016/2093171     Document Type: Article

References (51)

1. A. Ouwehand, E. Isolauri, and S. Salminen, "The role of the intestinal microflora for the development of the immune system in early childhood," European Journal of Nutrition, vol. 41, supplement 1, pp. I32-I37, 2002.
2. T. S. Stappenbeck, L. V. Hooper, and J. I. Gordon, "Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells," Proceedings of theNationalAcademy of Sciences of the United States of America, vol. 99, no. 24, pp. 15451-15455, 2002.
3. T. Klaenhammer, E. Altermann, F. Arigoni et al., "Discovering lactic acid bacteria by genomics," Antonie van Leeuwenhoek, vol. 82, no. 1-4, pp. 29-58, 2002.
4. K. Makarova, A. Slesarevb, Y. Wolf et al., "Comparative genomics of the lactic acid bacteria," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 42, pp. 15611-15616, 2006.
5. E. Esteve,W. Ricart, and J.-M. Fernández-Real, "Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiote co-evolve with insulin resistance" Current Opinion in Clinical Nutrition and Metabolic Care, vol. 14, no. 5, pp. 483-490, 2011.
6. F. Backhed, H. Ding, T. Wang et al., "The gut microbiota as an environmental factor that regulates fat storage," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 44, pp. 15718-15723, 2004.
7. M. Bajzer and R. J. Seeley, "Physiology: obesity and gut flora," Nature, vol. 444, no. 7122, pp. 1009-1010, 2006.
8. P. J. Turnbaugh, M. Hamady, T. Yatsunenko et al., "A core gut microbiome in obese and lean twins," Nature, vol. 457, no. 7228, pp. 480-484, 2009.
9. P. J. Turnbaugh, R. E. Ley, M. A. Mahowald, V. Magrini, E. R. Mardis, and J. I. Gordon, "An obesity-associated gut microbiome with increased capacity for energy harvest," Nature, vol. 444, no. 7122, pp. 1027-1031, 2006.
10. R. E. Ley, F. Bäckhed, P. Turnbaugh et al., "Obesity alters gut microbial ecology," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 31, pp. 11070-11075, 2005.
11. V. R. Velagapudi, R. Hezaveh, C. S. Reigstad et al., "The gut microbiota modulates host energy and lipid metabolism in mice," Journal of Lipid Research, vol. 51, no. 5, pp. 1101-1112, 2010.
12. M. Diamant, E. E. Blaak, and W. M. de Vos, "Do nutrient-gutmicrobiota interactions play a role in human obesity, insulin resistance and type 2 diabetes" Obesity Reviews, vol. 12, no. 4, pp. 272-281, 2011.
13. A. M. Caricilli, P. K. Picardi, L. L. de Abreu et al., "Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice," PLoS Biology, vol. 9, no. 12, Article IDe1001212, 2011.
14. P. D. Cani, S. Possemiers, T. Van DeWiele et al., "Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability," Gut, vol. 58, no. 8, pp. 1091-1103, 2009.
15. D. J. Drucker, "Enhancing incretin action for the treatment of type 2 diabetes," Diabetes Care, vol. 26, no. 10, pp. 2929-2940, 2003.
16. D. J. Drucker and B. Yusta, "Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2," Annual Review of Physiology, vol. 76, pp. 561-583, 2014.
17. C. S. Marathe, C. K. Rayner, K. L. Jones, and M. Horowitz, "Glucagon-like peptides 1 and 2 in health and disease: a review," Peptides, vol. 44, pp. 75-86, 2013.
18. P. B. Eckburg, E. M. Bik, C. N. Bernstein et al., "Microbiology: diversity of the human intestinal microbial flora," Science, vol. 308, no. 5728, pp. 1635-1638, 2005.
19. S. R. Gill, M. Pop, R. T. DeBoy et al., "Metagenomic analysis of the human distal gut microbiome," Science, vol. 312, no. 5778, pp. 1355-1359, 2006.
20. Y. S. Zhou, B. Li et al., "A rat model of type 2 diabetes mellitus induced by high fat chow and low dose streptozocin injection," Acta Laboratorium Animals Scientia Sinica, vol. 13, no. 3, pp. 154-158, 2005.
21. Y. Jialin, L. Guo, L. Youpin et al., "Establishing a rat model similar to the adult patient of the general type 2 diabetes by longterm fat-enriched fed and lower dose of streptozocin-treated rats," Acta Laboratorium Animals Scientia Sinica, vol. 11, no. 3, pp. 138-141, 2003.
22. K. R. Amato, C. J. Yeoman, A. Kent et al., "Habitat degradation impacts black howler monkey (Alouatta pigra) gastrointestinal microbiomes," ISME Journal, vol. 7, no. 7, pp. 1344-1353, 2013.
23. P. D. Schloss, S. L. Westcott, T. Ryabin et al., "Introducing mothur: open-source, platform-independent, communitysupported software for describing and comparing microbial communities," Applied and EnvironmentalMicrobiology, vol. 75, no. 23, pp. 7537-7541, 2009.
24. G. R. Warnes, B. Bolker, L. Bonebakker et al., gplots: Various R Programming Tools for Plotting Data, Version 2. 17. 0, 2015.
25. J. R. White, N. Nagarajan, and M. Pop, "Statistical methods for detecting differentially abundant features in clinical metagenomic samples," PLoS Computational Biology, vol. 5, no. 4, Article ID e1000352, 2009.
26. Y. L. Wu, G. X. Xi et al., "An experimental study of impaired glucose tolerance in Wistar rats," Chinese Remedies & Clinics, vol. 7, no. 4, pp. 281-283, 2007.
27. M. Cotta and R. Forster, "The family lachnospiraceae, including the genera butyrivibrio, lachnospira and roseburia," in The Prokaryotes: Volume 4: Bacteria: Firmicutes, Cyanobacteria, pp. 1002-1021, Springer, Berlin, Germany, 3th edition, 2006.
28. J. M. W. Wong, R. de Souza, C. W. C. Kendall, A. Emam, and D. J. A. Jenkins, "Colonic health: fermentation and short chain fatty acids," Journal of Clinical Gastroenterology, vol. 40, no. 3, pp. 235-243, 2006.
29. H. J. Flint, K. P. Scott, S. H. Duncan, P. Louis, and E. Forano, "Microbial degradation of complex carbohydrates in the gut," Gut Microbes, vol. 3, no. 4, pp. 289-306, 2012.
30. X. Ze, S. H. Duncan, P. Louis, and H. J. Flint, "Ruminococcus bromii is a keystone species for the degradation of resistant starch in the human colon," ISMEJournal, vol. 6, no. 8,pp. 1535-1543, 2012.
31. R. E. Ley, "Obesity and the human microbiome," Current Opinion in Gastroenterology, vol. 26, no. 1, pp. 5-11, 2010.
32. S. H. Duncan, G. E. Lobley, G. Holtrop et al., "Human colonic microbiota associated with diet, obesity and weight loss," International Journal of Obesity, vol. 32, no. 11, pp. 1720-1724, 2008.
33. V. Mai, Q. M. McCrary, R. Sinha, and M. Glei, "Associations between dietary habits and body mass index with gut microbiota composition and fecal water genotoxicity: an observational study in African American and Caucasian American volunteers," Nutrition Journal, vol. 8, article 49, 2009.
34. R. Jumpertz, D. S. Le, P. J. Turnbaugh et al., "Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans," The American Journal of Clinical Nutrition, vol. 94, no. 1, pp. 58-65, 2011.
35. O. O. Erejuwa, S. A. Sulaiman, and M. S. Ab Wahab, "Modulation of gut microbiota in the management of metabolic disorders: The prospects and challenges," International Journal of Molecular Sciences, vol. 15, no. 3, pp. 4158-4188, 2014.
36. P. J. Turnbaugh, F. Bäckhed, L. Fulton, and J. I. Gordon, "Dietinduced obesity is linked to marked but reversible alterations in themouse distal gut microbiome," Cell Host and Microbe, vol. 3, no. 4, pp. 213-223, 2008.
37. J. Qin, J. Wang, Y. Li et al., "A metagenome-wide association study of gut microbiota in type 2 diabetes," Nature, vol. 490, no. 7418, pp. 55-60, 2012.
38. T. Wang, G. Cai, Y. Qiu et al., "Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers," The ISME Journal, vol. 6, no. 2, pp. 320-329, 2012.
39. K. M. Maslowski, A. T. Vieira, A. Ng et al., "Regulation of inflammatory responses by gut microbiota and chemoattractant receptorGPR43," Nature, vol. 461, no. 7268, pp. 1282-1286,2009.
40. C. De Filippo, D. Cavalieri, M. Di Paola et al., "Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa," Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 33, pp. 14691-14696, 2010.
41. K. Forslund, F. Hildebrand,T. Nielsen et al., "Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota," Nature, vol. 528, no. 7581, pp. 262-266, 2015.
42. G. L. Hold, A. Schwiertz, R. I. Aminov,M. Blaut, and H. J. Flint, "Oligonucleotide probes that detect quantitatively significant groups of butyrate-producing bacteria in human feces," Applied and Environmental Microbiology, vol. 69, no. 7, pp. 4320-4324, 2003.
43. N. Becker, J. Kunath, G. Loh, and M. Blaut, "Human intestinal microbiota: characterization of a simplified and stable gnotobiotic rat model," Gut Microbes, vol. 2, no. 1, pp. 25-33, 2011.
44. S. Nobaek, M.-L. Johansson, G. Molin, S. Ahrné, and B. Jeppsson, "Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome," The American Journal of Gastroenterology, vol. 95, no. 5, pp. 1231-1238, 2000.
45. G. T. Macfarlane and S. Macfarlane, "Human colonic microbiota: ecology, physiology and metabolic potential of intestinal bacteria," Scandinavian Journal of Gastroenterology, vol. 32, supplement 222, pp. 3-9, 1997.
46. E. G. Zoetendal, A. D. L. Akkermans, W. M. Akkermansvan Vliet, J. A. G. M. De Visser, and W. M. De Vos, "The host genotype affects the bacterial community in the human gastrointestinal tract,"Microbial Ecology inHealth and Disease, vol. 13, no. 3, pp. 129-134, 2001.
47. N.-R. Shin, J.-C. Lee, H.-Y. Lee et al., "An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice," Gut, vol. 63, no. 5, pp. 727-735, 2014.
48. C. Reasner, L. Olansky, T. L. Seck et al., "The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetesmellitus,"Diabetes, Obesityand Metabolism, vol. 13, no. 7, pp. 644-652, 2011.
49. B. Ahrén, S. L. Johnson, M. Stewart et al., "HARMONY 3: 104-week randomized, double-blind, placebo-and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin," Diabetes Care, vol. 37, no. 8, pp. 2141-2148, 2014.
50. S. Enjoji, T. Ohama, and K. Sato, "Regulation of epithelial cell tight junctions by protease-activated receptor 2," The Journal of Veterinary Medical Science, vol. 76, no. 9, pp. 1225-1229, 2014.
51. N. Wronkowitz, S. W. Görgens, T. Romacho et al., "Soluble DPP4 induces inflammation and proliferation of human smoothmuscle cells via protease-activated receptor 2," Biochimica et Biophysica Acta, vol. 1842, no. 9, pp. 1613-1621, 2014.